other material
confidence high
sentiment positive
materiality 0.95
Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day
Biohaven Ltd.
- Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
- 54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.
- BHV-1300 reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized thyroid hormones within weeks in Graves' disease patients.
- BHV-1400 reduced Gd-IgA1 >60% within hours and 70% within one month in IgA nephropathy, with early eGFR and UPCR improvements.
- Both degrader programs showed well-tolerated safety profiles with no serious adverse events; pivotal Phase 3 trials expected to initiate mid-2026.